« Back
Home /
Vamifeport

Vamifeport

Item no.	TMO-T39520-200mg
Manufacturer	TargetMol
CASRN	2095668-10-1
Amount	200 mg
Quantity options	100 mg 10 mg 1 mL 200 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	0,98
Smiles	Fc1cccnc1CNC(=O)c1coc(CCNCCc2nc3ccccc3[nH]2)n1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	VIT-2763
Shipping condition	Cool pack
Available
Manufacturer - Targets	Ferroptosis
Shipping Temperature	cool pack
Storage Conditions	-20°
Molecular Weight	408, 43
Description	Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.
Bioactivity	VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of Î²-thalassemia.
Pathways	Apoptosis

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 200 mg

available

Request delivery time